Outlook Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Outlook Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Outlook Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Outlook Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Outlook Therapeutics Inc (Outlook Therapeutics) is a late clinical-stage biopharmaceutical company that develops ophthalmic therapies for the treatment of retinal diseases. The company’s lead candidate ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma), ophthalmic bevacizumab formulation for the treatment of retinal diseases and neovascular age-related macular degeneration (nAMD). It markets its products in Germany, Austria, and the UK regions. The company collaborates with Cencora to support commercial launch of products. Outlook Therapeutics is headquartered in Newark, New Jersey, the US.
Headquarters
United States of America
Address
Unit 100, 111 South Wood Avenue, Iselin, Newark, New Jersey, 08830
Website
outlooktherapeutics.com
Telephone
1 609 6193990
No of Employees
17
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OTLK (NASD)
Revenue (2024)
$1.4M
EPS
XYZ
Net Income (2024)
XYZ
17.2%
(2024 vs 2023)
Market Cap*
$168.0M
Net Profit Margin (2024)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Outlook Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| ONS-5010/LYTENAVA: Retinal Diseases and Neovascular Age-Related Macular Degeneration (nAMD) | Lytenava |
Competitor Comparison
| Key Parameters | Outlook Therapeutics Inc | Merck & Co Inc | AbbVie Inc | Novartis AG | Bayer AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | Germany |
| City | Newark | Rahway | North Chicago | Basel | Leverkusen |
| State/Province | New Jersey | New Jersey | Illinois | Basel-Stadt | Nordrhein-Westfalen |
| No. of Employees | 17 | 75,000 | 57,000 | 75,267 | 87,830 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Faisal G. Sukhtian | Chairman | Executive Board | 2025 | 41 |
| Robert C. Jahr | Chief Executive Officer; Director; President | Executive Board | 2025 | 54 |
| Lawrence A. Kenyon | Chief Financial Officer; Executive Vice President; Treasurer; Director; Secretary | Executive Board | 2018 | 60 |
| Laura Cantrell | Vice President - Corporate Strategy and Business Development | Senior Management | 2026 | - |
| Yezan Haddadin | Director | Non Executive Board | 2017 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer